HomeStocksLAURUSLABS

L

Laurus Labs

LAURUSLABS Share Price

Healthcare
mtf MTF 4.01x

909.85

20.60 (2.32%)profit

as on 29 Jul 2025 at 15:58

1D
img
626
img
45.45% Sell
Bulb

Today Laurus Labs opened at 889.00 while its previous close was at 889.25. In todays trading session LAURUSLABS reached a high of 913.70 and low of 875.65. The average traded price for today is 896.87. The 50 DMA stands at 704.34 and 200 DMA is at 598.73. Looking at intraday trend, the stock is in Uptrend.

chartsarrowTradingViewarrow
TradingView Logo

Get 10+ Layouts, 100+ Indicators, Custom Timeframes & All Drawing Tools for FREE.

LAURUSLABS Stock Performance

Markets Today

High

913.70

Low

875.65

Open at

889.00

Prev Close

889.25

Volumes

49,89,767

Avg Price

896.87

Lower Circuit

818.90

Upper Circuit

1,000.80

Last Traded Details

Quantity

1

Time

15:58:46

Price Movement

875.65
909.85
913.70
Loss 3.91%down side
up side0.42% profit

Historical Performance

3 M High

913.70

3 M Low

572.25

1 Yr High

913.70

1 Yr Low

417.70

3 Yr High

913.70

3 Yr Low

278.85

5 Yr High

913.70

5 Yr Low

151.59

1-Year Performance

417.70
909.85
913.70
loss3.91%down side
up side0.42% profit

LAURUSLABS Analyst Rating

Sell

Analysts have suggested that investors can Sell this Stock

- By Refinitiv from 11 analysts

Buy

36.36%

Hold

18.18%

Sell

45.45%


LAURUSLABS Latest News

View All News arrow

Laurus Labs Reports Strong Q1 Performance with 31% Revenue Growth, CDMO Business Drives Margins

sentiment_img

Laurus Labs delivered robust quarterly results with revenues of INR 1,570 crores, marking 31% year-on-year growth. The CDMO business showed strong performance with sales of INR 493 crores, driven by mid-to-late stage NCE deliveries and increased Big Pharma projects. The company maintains over 110 active CDMO projects across Human Health, Animal Health, and Crop Sciences. Gross margins expanded to 59%, while EBITDA margins improved by 10.5 percentage points to approximately 25%. The Generics division grew 12% to INR 1,048 crores, supported by volume expansion in ARV and developed market sales. Laurus Bio reported flat sales of INR 29 crores due to customer-specific scale-up challenges. The company announced three major capacity expansions including microbial fermentation facility at Vizag, gene therapy and ADC facility at Shameerpet, and formulation facility under Krka joint venture. Management expects CDMO contribution to potentially reach 50% of revenue in the medium term, up from current 30%. The company invested INR 265 crores in capex and maintains net debt of INR 2,388 crores with debt-to-EBITDA ratio of 1.8.

8 hours ago

Laurus Labs Targets 25% EBITDA Margins, CDMO Business to Exceed 30% Revenue Share

sentiment_img

Laurus Labs expects gross margins to remain in the 55-60% range for the financial year ending in March, driven by higher contribution from non-antiretroviral products and growing CDMO business. The company is targeting 25% EBITDA margins for the year, up from 20% last year. CEO Satyanarayana Chava expects CDMO revenue contribution to exceed 30% this year, with the business targeting ₹2,000 crore in CDMO revenue annually. The company supplied three new chemical entities for commercial supply in the last two quarters. Laurus Labs sees minimal impact from the US biotech funding slowdown as most revenue comes from big pharma companies with strong pipelines rather than small biotech firms. The majority of CDMO revenues are from late-phase or commercial stage molecules rather than early-stage development.

1 day ago

Laurus Labs Sets Financial Targets with Gross Margins at 55-60% and CDMO Revenue Growth Plans

sentiment_img

Laurus Labs has outlined its financial expectations, targeting gross margins to remain between 55-60%. The company plans to maintain net debt at no more than 50% of annual revenue and keep its debt/EBITDA ratio at 2-2.5x. Laurus Labs expects ARV revenue of approximately Rs 2,500 crore with a margin of Rs 200 crore. The pharmaceutical company anticipates its CDMO (Contract Development and Manufacturing Organization) contribution to increase from the current 30% to around 50% of total revenue in the medium term.

1 day ago

LAURUSLABS Share Price History

View Price History arrow

Close Price

Volume

LAURUSLABS share price in last 10 trading sessions

DayOpenCloseChange%Day HighDay LowVolume
28 Jul 2025833.00889.25
6.75% profit
901.50828.051,76,17,498
25 Jul 2025839.10837.75
-0.16% Loss
846.00825.0552,68,018
24 Jul 2025823.95836.50
1.52% profit
842.00817.1523,58,313
23 Jul 2025825.00822.50
-0.30% Loss
825.90817.0511,56,632
22 Jul 2025831.90823.35
-1.03% Loss
832.00815.009,47,754
21 Jul 2025827.20829.45
0.27% profit
833.90824.1512,16,659
18 Jul 2025825.10827.00
0.23% profit
829.00814.509,89,477
17 Jul 2025825.90821.50
-0.53% Loss
830.00815.2015,18,302
15 Jul 2025825.75827.05
0.16% profit
834.35820.4520,80,040
14 Jul 2025788.20823.85
4.52% profit
827.50788.2050,83,453

LAURUSLABS Fundamentals

View Fundamentals arrow

Company Valuation

Market Cap (₹ Cr.)

49,064

PE Ratio

94.20

PB Ratio

10.72

Dividend Yield

0.13%

ROE

7.70%

ROCE

12.08%

Book Value (₹)

82.89

Face Value (₹)

2.00


Share Holding Pattern

Held ByJun 2024Sep 2024Dec 2024Mar 2025Jun 2025
Promoters
27.18%27.18%27.62%27.62%27.59%
Domestic Institutional Investors (DII)
13.56%13.05%12.74%11.77%11.94%
Foreign Institutional Investors (FII)
25.67%26.08%25.56%25.52%25.70%
Public Investors
22.68%22.67%22.72%23.65%23.12%
Government
0.00%0.00%0.00%0.00%0.00%

Promoters

Domestic Institutional Investors (DII)

Foreign Institutional Investors (FII)

Public Investors

Government


LAURUSLABS Investment Returns

1 Week

1 Month

3 Months

6 Months

9 Months

SIP Logo

Create Wealth in Longterm with Weekly and Monthly SIP in Stocks.


LAURUSLABS Technicals

View Technicals arrow

Moving Averages

PeriodSimpleSignal
5-SMA841.87Bullish
10-SMA833.82Bullish
20-SMA801.65Bullish
50-SMA704.34Bullish
100-SMA651.96Bullish
200-SMA598.73Bullish

Technical Indicators

IndicatorValueAction
RSI(14)87.87Overbought
ATR(14)21.97Volatile
STOCH(9,6)85.52Overbought
STOCH RSI(14)56.25Neutral
MACD(12,26)1.88Bullish
ADX(14)60.42Very Strong Trend

Summary of Technical Indicators for LAURUSLABS


LAURUSLABS Financials Summary
View By:
Revenue
EBITDA
Net Profit
EPS
Revenue

In Crores

Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025
1,1971,2281,4251,7791,580

LAURUSLABS Financials

View By:

Income Statement

In Crores

Quarterly StatementJun 2024Sep 2024Dec 2024Mar 2025Jun 2025
Revenue1,1971,2281,4251,7791,580
Expenses1,0241,0451,1301,3001,187
Operating Profit171178285421382
Operating Profit Margin %14%15%20%24%24%
Other Income3595910
EBITDA174183295479393
Interest4953585652
Depreciation106108106110117
Profit Before Tax1923131312224
Tax %31%13%29%25%28%
Net Profit132093233162
EPS00243

Balance Sheet

In Crores

Yearly Balance SheetMar 2021Mar 2022Mar 2023Mar 2024Mar 2025
Share Capital107108108108108
Reserve & Surplus2,4903,2443,9304,0034,365
Minority Interest38115130
Non Current Liabilities6939281,1801,1591,193
Current Liabilities2,4572,6812,4323,1123,540
Total Liabilities5,7516,9687,6608,3879,336
Fixed Assets2,1712,6533,4093,8904,123
Capital Work in Progress362813551423458
Investments33150124233
Other Assets3,2153,4723,6513,9504,521
Total Assets5,7516,9687,6608,3879,336

Cash Flow

In Crores

Yearly Cash FlowMar 2021Mar 2022Mar 2023Mar 2024Mar 2025
Operating Activities733911994666602
Investing Activities-941-915-997-822-680
Financing Activities25530-2725039
Net Cash Flow4727-3093-39

Past Corporate Actions

DateCorporate ActionInformation
09 Jul 2025
Quarterly Result Announcement
NA
15 May 2025
Annual General Meeting
NA
24 Apr 2025
Dividend
₹ 0.80 /share
10 Apr 2025
Quarterly Result Announcement
NA
06 Jan 2025
Quarterly Result Announcement
NA
ScanX Logo

Get In-depth View of LAURUSLABS Quaterly Results, Balance Sheet, Cashflows & Corporate Action.

Use Screener

LAURUSLABS Revenue Growth

All values are in Crores

Revenue

Profit

Loss

Financial YearRevenueRevenue GrowthNet ProfitProfit Growth
FY 2024-255,317
8.41% profit
380
70.04% profit
FY 2023-244,860
-16.65% Loss
224
-70.58% Loss
FY 2022-235,789
22.66% profit
760
1.37% profit

LAURUSLABS Options Snapshot

View In-depth arrow
Top 5 Traded ContractsExpiry DateLTPChangeChange %VolumeOpen InterestOI Change %

LAURUSLABS Futures Snapshot

View In-depth arrow
Monthly ContractsDays for ExpiryLTPChangeChange %VolumeOpen InterestOI Change %
LAURUSLABS JUL FUT3

910.20

21.802.4571,17,9001,18,38,800-9.19
LAURUSLABS AUG FUT31

914.75

21.802.4492,15,7001,25,63,00028.10
LAURUSLABS SEP FUT64

917.80

20.302.262,85,6005,81,4000.88






What’s New In The Market
news

At this moment, No news for this stock


FAQs

Laurus Labs share price as of today is ₹ 909.85 as on 29 Jul 2025 at 15:58.
The 52W high of Laurus Labs is ₹ 913.70 and 52W low is ₹ 417.70 as of 29 Jul 2025 at 15:58.
The past returns of Laurus Labs share are -
  • Past 1 year: 101.74%
  • Past 3 years: 74.07%
  • Past 5 years: 495.57%
The PE and PB ratio of Laurus Labs stands at 94.20 and 10.72 respectively as on 29 Jul 2025 at 15:58.
The EPS of Laurus Labs is 3.02 for the quarter ended Jun 2025 and 6.65 for the financial year 2024-25.
The shareholding pattern of Laurus Labs is as follows:
  • DIIs - 11.94%
  • FII - 25.70%
  • Promoters - 27.59%
  • Public Investors 23.12%
  • Goverenment - 0.00%
Yes, you can buy shares of Laurus Labs online by opening Demat account with Dhan.
If you are a Dhan user already, you can buy Laurus Labs stocks from Dhan Trading App or Web Trading Platform. If you are new to Dhan follow the below steps:
  1. Download the Dhan App to Open a Demat Account
  2. Navigate to the “Money Tab”
  3. Add money to your account
  4. Search for Laurus Labs share
  5. Tap on “Buy”
With Dhan you can start a daily, weekly or monthly SIP in Laurus Labs.
You can easily buy the shares of Laurus Labs even after the markets are closed using the After Market Order feature on Dhan Trading App.
Candle bars with Screen
Invest in LAURUSLABS
Candle bars with Screen

Pay Zero Brokerage on Delivery

Candle bars with Screen

Open FREE Demat Account

Indian Flag

+91

Or Scan the QR Code to download the Dhan App

QR code Logo


Invest & Trade with a Trading
Platform That's icon

Open your Dhan Account in minutes!


border

Explore  |  Sitemap

*All securities mentioned on this website are exemplary and not recommendatory.

*Current prices on the website are delayed by 15 mins, login to check live prices.

We are bullish on India, we are bullish on India's prospects to be one of the largest economies in the world. We believe that the stock market provides a unique opportunity for all of India's traders and investors to participate in the growth story of the country.

Yet, most investing & trading platforms in India have remained more or less the same over the past decade. Times have changed and retail traders and investors have become smarter about managing their trades and money. Modern traders & investors require an online trading platform that helps them keep up with the technological advancements of our time.

That's why we're building Dhan - to help you trade, to help you invest, and to help you participate in India's growth stock via the stock market with awesome features and an incredible experience.

©2021-2025 Raise Securities Private Limited (formerly Moneylicious Securities Private Limited). All rights reserved. CIN: U74999MH2012PTC433549 Raise Securities is part of Raise Financial Services.

SEBI Stock Broker Registration No: INZ000006031 | Depository Participant (CDSL) ID: IN-DP-289-2016
Exchange Membership No. : NSE: 90133 | BSE: 6593 | MCX: 56320
Registered Office: Unit No. 2201, 22nd Floor, Gold Medal Avenue, S.V. Road, Beside Patel Petrol Pump, Piramal Nagar, Goregaon West, Mumbai – 400104
Corporate Office: 302, The Western Edge I, Off Western Express Highway, Borivali East, Mumbai - 400066, Maharashtra, India. Customer Care: 9987761000.


For any query / feedback / clarifications, email at help@dhan.co.

In case of grievances for any of the services rendered by Raise Securities Private Limited, please write to grievance@dhan.co (for NSE, BSE and MCX) or grievancedp@dhan.co (for Depository Participant). Please ensure that you carefully read the Risk Disclosure Document as prescribed by SEBI, our Terms of Use and Privacy Policy. Compliance Officer: Mr. Manish Garg and Mobile: 8655740961 Email: complianceofficer@dhan.co To lodge your complaints using SEBI SCORES, click here.


Disclaimer: All communications with the client via chat, phone, or email are for support purposes only. Any commitments or statements made by the agent (human or virtual) shall not be binding on the company.


DHAN is a brand owned by Raise Securities Private Limited. All DHAN clients are registered under Raise Securities Private Limited. Clients are advised to refer to our company as Raise Securities Private Limited when communicating with regulatory authorities.


Procedure to file a complaint on SEBI SCORES: Register on SCORES portal. Mandatory details for filing complaints on SCORES: Name, PAN, Address, Mobile Number, E-mail ID. Benefits: Effective Communication, Speedy redressal of the grievances


Disclaimer: Investment in the securities market are subject to market risks, read all the related documents carefully before investing. Brokerage will not exceed the SEBI prescribed limit


Attention investors:

  1. Stock brokers can accept securities as margins from clients only by way of pledge in the depository system w.e.f September 01, 2020.
  2. Update your e-mail and phone number with your stock broker / depository participant and receive OTP directly from depository on your e-mail and/or mobile number to create pledge.
  3. Check your securities / MF / bonds in the consolidated account statement issued by NSDL/CDSL every month.

Note: As a policy we do not give stock tips or recommendations and have not authorized anyone to give this on behalf of us. If you know anyone claiming to be a part of Dhan / / Raise or our associate companies or partners and offering such services, please report us on help@dhan.co. Important Information for Investors: To prevent unauthorized transactions in your trading / demat account, do not share your account details, credentials or any personal details with anyone. Keep your mobile number updated with your Stock Broker, Depository Participant and ensure that the same is registered with Stock Exchanges, Depository and KRAs. You will receive alerts and information on your registered mobile number / email for debit and other important transactions in your demat account directly from CDSL / Exchange on the same day. KYC is one time exercise while dealing in securities markets - once KYC is done through a SEBI registered intermediary (Stock Broker, DP, Mutual Fund, etc.), you need not undergo the same process again when you approach another intermediary. No need to issue cheques by investors while subscribing to IPO. Just write the bank account number and sign in the application form to authorise your bank to make payment in case of allotment. No worries for refund as the money remains in investor's account. This is issued in the interest of investors.


Raise Securities Private Limited also known as Dhan is only an order collection platform that collects orders on behalf of clients and places them on BSE StarMF for execution. Client expressly agrees that Dhan is not liable or responsible and does not represent or warrant any damages regarding non- execution of orders or any incorrect execution of orders with regard to the funds chosen by the client or due to, but not being limited to, any link/system failure, delay in transfer of the funds on account of any unforeseen circumstances/issues in the banking system/payment aggregators or any other problems that may result in a delay in crediting the funds into the BSE Star MF's bank account.


Mutual fund investments are subject to market risks, read all scheme related documents carefully before investing. Dhan is not a distributor or agent of any mutual fund. Mutual Funds are not exchange-traded products. Any related disputes will not have access to the Exchange-investor redressal forum or arbitration mechanism. For other disclaimers please refer https://dhan.co/advertisement-disclaimer/


Download client registration documents (Rights & Obligations, Risk Disclosure Document, Do's & Don'ts) in vernacular language: BSE | NSE | MCX


Kindly, read the Advisory Guidelines of BSE | NSE | MCX for investors as prescribed by the exchange with reference to their circular dated 27th August, 2021 regarding investor awareness and safeguarding client's assets


Important Links: SEBI | BSE | NSE | MCX | CDSL | SCORES | ODR Portal | Investor Charter for Stock Brokers | Investor Charter for DP | UCC Advisory | e-Voting for Shareholders | NCL Client Collateral details |
MCXCCL Client Collateral details

Important Information: Terms of Usage | Disclaimers | Privacy Policy | Grievances | Risk Management Policy | Risk Disclosure | Advertisement Disclaimer | Referral Terms & Conditions | Saarthi 2.0 Mobile App for Investors